Show simple item record

dc.contributor.authorPerez-Lloret S.
dc.contributor.authorOtero-Losada M.
dc.contributor.authorToblli J.E.
dc.contributor.authorCapani F.
dc.date.accessioned2020-09-02T22:25:47Z
dc.date.available2020-09-02T22:25:47Z
dc.date.issued2017
dc.identifier10.1080/13543784.2017.1371133
dc.identifier.citation26, 10, 1163-1173
dc.identifier.issn13543784
dc.identifier.urihttps://hdl.handle.net/20.500.12728/5777
dc.descriptionIntroduction: Currently, available therapies for Parkinson’s disease (PD) are symptomatic. Therefore, the search for neuroprotective drugs remains a top priority. Areas covered: In this review, the potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System (RAS) in PD will be explored. Expert opinion: The importance of nigrostriatal local RAS has only begun to be unraveled in the last decades. On one hand, there is a complex feedback cycle between RAS and dopamine (DA). On the other hand, RAS affects dopaminergic neurons vulnerability. Neuroprotective effects in animal PD models have been shown for the angiotensin-converting enzyme (ACE) inhibitors captopril and perindopril, and the AT1 receptor antagonists losartan, candesartan and telmisartan. These effects appear to be mediated by a reduction in the overproduction of reactive oxygen species. In a proof-of-concept, randomized, double-blind, crossover study in PD patients, perindopril enhanced the effect of levodopa without inducing dyskinesias. There has not been any clinical trial exploring the neuroprotective effect of RAS drugs, but one cohort study in hypertensive patients suggested a protective effect of ACE inhibitors on PD risk. RAS is a promising target for symptomatic and neuroprotective therapies in PD. Further studies in PD animal models and patients are warranted. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
dc.language.isoen
dc.publisherTaylor and Francis Ltd
dc.subjectangiotensin
dc.subjectneuroprotection
dc.subjectParkinson’s disease
dc.subjectrenin
dc.subjecttreatment
dc.subjectangiotensin 1 receptor antagonist
dc.subjectangiotensin II
dc.subjectangiotensin receptor
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectdopamine
dc.subjectlevodopa
dc.subjectreactive oxygen metabolite
dc.subjectangiotensin 1 receptor antagonist
dc.subjectantiparkinson agent
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectdopamine
dc.subjectneuroprotective agent
dc.subjectreactive oxygen metabolite
dc.subjectbrain region
dc.subjectdopaminergic nerve cell
dc.subjectdrug effect
dc.subjectdrug targeting
dc.subjecthuman
dc.subjectlevodopa-induced dyskinesia
dc.subjectnerve degeneration
dc.subjectneuroprotection
dc.subjectnonhuman
dc.subjectParkinson disease
dc.subjectrenin angiotensin aldosterone system
dc.subjectReview
dc.subjectanimal
dc.subjectdrug design
dc.subjectdrug effects
dc.subjectmetabolism
dc.subjectmolecularly targeted therapy
dc.subjectParkinson disease
dc.subjectpathophysiology
dc.subjectrandomized controlled trial (topic)
dc.subjectrenin angiotensin aldosterone system
dc.subjectAngiotensin II Type 1 Receptor Blockers
dc.subjectAngiotensin-Converting Enzyme Inhibitors
dc.subjectAnimals
dc.subjectAntiparkinson Agents
dc.subjectDopamine
dc.subjectDrug Design
dc.subjectHumans
dc.subjectMolecular Targeted Therapy
dc.subjectNeuroprotective Agents
dc.subjectParkinson Disease
dc.subjectRandomized Controlled Trials as Topic
dc.subjectReactive Oxygen Species
dc.subjectRenin-Angiotensin System
dc.titleRenin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
dc.typeReview


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record